profit from every CA$100 of sales.
CA$0CA$100
Knight Therapeutics
CA$12.06+0.08% today
+108.7% in 1 year
1-year low CA$5.761-year high CA$12.06
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Knight Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from CA$100 of sales | Sales growth a year | Price per CA$1 of profit |
|---|---|---|---|
| Knight Therapeutics | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Knight Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 1.2×
- 2.6×
- 33.6×
- –
- 3.0%
- -0.5%
- –
Profitability
- 44.5%
- -0.5%
- -1.2%
- –
- 0.3%
- -0.6%
- –
- –
- –
- –
Growth
- +15.3%
- –
- –
- –
- −4.7%
Financial health
- 0.0×
- 0.10
- –
- 0.4×
- 2.39
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 952
Bottom 20%of 883
Top 35%of 888
Top 36%of 987
News
Knight-Swift projects Q4 2026 adjusted EPS of $0.78-$0.84 as it expects truckload operating income to meaningfully improve sequentiallySeeking Alpha · Oct 22, 2026Nike co-founder Phil Knight to donate $1.1 billion to Oregon medical centerCNBC · Sep 15, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
58No pass
Philip Fisher
49No pass
Peter Lynch
58No pass
Joel Greenblatt
0No pass
Charlie Munger
45No pass
Terry Smith
39No pass
Questions about Knight Therapeutics
Is Knight Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Knight Therapeutics AI analysis
What does Knight Therapeutics do?
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. It is in Drug Manufacturers - Specialty & Generic.
Is Knight Therapeutics stock halal?
Yes. Knight Therapeutics passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Knight Therapeutics stock done over the past year?
Up 108.7% over the past twelve months, to CA$12.06. It traded between CA$5.76 and CA$12.06, close to its high.
Who are Knight Therapeutics's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Knight Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.